Abstracts tagged "lupus nephritis and renal disease"

Abstract Number: 724 • 2018 ACR/ARHP Annual Meeting
Are Traditional Biomarkers of Lupus Associated with Renal Pathology in Lupus Nephritis?
Kelly Liang¹, Kimberly P. Liang², Yaming Li³, Alex Hurd³, Douglas Landsittel⁴ and Sheldon Bastacky⁵, ¹Medicine, Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Biostatistics, University of Pittsburgh, Pittsburgh, PA, ⁴Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, ⁵Pathology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Traditional biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN) include serum creatinine (Cr), complement levels (C3/C4), double-stranded DNA antibody (dsDNA), erythrocyte sedimentation…
Abstract Number: 774 • 2018 ACR/ARHP Annual Meeting
Clinical Variables and Serologic Markers of Disease Activity Do Not Aid in Early Recognition of Patients with Tubulointerstitial Disease Who Have No Significant Renal Impairment at Time of Biopsy
Alejandra Londono Jimenez¹, Beatrice Goilav², Maria Salgado Guerrero³, Kimberly A. Lynch⁴, Wenzhu B. Mowrey² and Anna R. Broder⁵, ¹Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Internal Medicine, Jacobi Medical Center, Bronx, NY, ⁴Internal Medicine, Montefiore Medical Center, Bronx, NY, ⁵Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Tubulointerstitial damage (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy/ (IF/TA) is associated with poor renal outcomes in lupus nephritis (LN)1. Glomerular…
Abstract Number: 2948 • 2018 ACR/ARHP Annual Meeting
Deconstructing the in Situ Myeloid Cell Microenvironment in Human Lupus Nephritis Tissue
Paul Hoover^1,2, Tony Jones², Cianna Leatherwood³, Sushrut Waikar⁴, Karen Costenbader³ and Nir Hacohen⁵, ¹Division of Rheumatology, Allergy, Immunology, Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Renal, Brigham and Women's Hospital, Boston, MA, ⁵Harvard Medical School, Boston, MA
Background/Purpose: The cell-types and pathways driving lupus nephritis (LN) are incompletely understood. The Accelerating Medicine Partnership lupus network Pathway Exploration and Analysis in RenaL disease…
Abstract Number: 9 • 2017 ACR/ARHP Annual Meeting
Renal Protective Effect of Antiplatelet Therapy in Antiphospholipid Antibody-Positive Lupus Nephritis Patients without the Antiphospholipid Syndrome
Hironari Hanaoka¹, Tomofumi Kiyokawa¹, Harunobu Iida¹, Yukiko Takakuwa¹, Takahiro Okazaki², Hidehiro Yamada³, Shoichi Ozaki⁴ and Kimito Kawahata¹, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ⁴Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. Since antiphospholipid syndrome (APS) is…
Abstract Number: 2838 • 2016 ACR/ARHP Annual Meeting
Histopatholgic Predictors of Poor Renal Outcomes in a Multi-Ethnic Cohort
Stacy Tanner¹, Dominick Santoriello², Shanthi Dhaduvai³, Thania Perez⁴, Anca D. Askanase⁵ and Laura Geraldino-Pardilla⁶, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Renal Pathology, Columbia University College of Physicians & Surgeons, New York, NY, ³Rheumatology, Carilion Clinic, Roanoke, VA, ⁴Columbia University College of Physicians & Surgeons, New York, NY, ⁵Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁶Columbia University College of Physicians & Surgeons, new york, NY
Background/Purpose: Lupus nephritis (LN) remains an important cause of morbidity and mortality in patients with SLE. Tubular atrophy and interstitial fibrosis on initial renal biopsies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].